Literature DB >> 34375171

Diagnostic Accuracy of Endobronchial Optical Coherence Tomography for the Microscopic Diagnosis of Usual Interstitial Pneumonia.

Sreyankar Nandy1,2,3, Rebecca A Raphaely1,3, Ashok Muniappan4,3, Angela Shih5,3, Benjamin W Roop1,2, Amita Sharma6,3, Colleen M Keyes1,3, Thomas V Colby7, Hugh G Auchincloss4,3, Henning A Gaissert4,3, Michael Lanuti4,3, Christopher R Morse4,3, Harald C Ott4,3, John C Wain4,3,8, Cameron D Wright4,3, Maria L Garcia-Moliner9, Maxwell L Smith7, Paul A VanderLaan3,10, Sarita R Berigei1,2, Mari Mino-Kenudson5,3, Nora K Horick11,3, Lloyd L Liang1, Diane L Davies4, Margit V Szabari1,2,3, Peter Caravan3,12,13, Benjamin D Medoff1,3, Andrew M Tager1,3, Melissa J Suter1,2,3, Lida P Hariri1,2,5,3.   

Abstract

Rationale: Early, accurate diagnosis of interstitial lung disease (ILD) informs prognosis and therapy, especially in idiopathic pulmonary fibrosis (IPF). Current diagnostic methods are imperfect. High-resolution computed tomography has limited resolution, and surgical lung biopsy (SLB) carries risks of morbidity and mortality. Endobronchial optical coherence tomography (EB-OCT) is a low-risk, bronchoscope-compatible modality that images large lung volumes in vivo with microscopic resolution, including subpleural lung, and has the potential to improve the diagnostic accuracy of bronchoscopy for ILD diagnosis.
Objectives: We performed a prospective diagnostic accuracy study of EB-OCT in patients with ILD with a low-confidence diagnosis undergoing SLB. The primary endpoints were EB-OCT sensitivity/specificity for diagnosis of the histopathologic pattern of usual interstitial pneumonia (UIP) and clinical IPF. The secondary endpoint was agreement between EB-OCT and SLB for diagnosis of the ILD fibrosis pattern.
Methods: EB-OCT was performed immediately before SLB. The resulting EB-OCT images and histopathology were interpreted by blinded, independent pathologists. Clinical diagnosis was obtained from the treating pulmonologists after SLB, blinded to EB-OCT. Measurements and Main
Results: We enrolled 31 patients, and 4 were excluded because of inconclusive histopathology or lack of EB-OCT data. Twenty-seven patients were included in the analysis (16 men, average age: 65.0 yr): 12 were diagnosed with UIP and 15 with non-UIP ILD. Average FVC and DlCO were 75.3% (SD, 18.5) and 53.5% (SD, 16.4), respectively. Sensitivity and specificity of EB-OCT was 100% (95% confidence interval, 75.8-100.0%) and 100% (79.6-100%), respectively, for both histopathologic UIP and clinical diagnosis of IPF. There was high agreement between EB-OCT and histopathology for diagnosis of ILD fibrosis pattern (weighted κ: 0.87 [0.72-1.0]). Conclusions: EB-OCT is a safe, accurate method for microscopic ILD diagnosis, as a complement to high-resolution computed tomography and an alternative to SLB.

Entities:  

Keywords:  idiopathic pulmonary fibrosis; interstitial lung disease; in vivo microscopy; in vivo optical imaging; usual interstitial pneumonia

Mesh:

Year:  2021        PMID: 34375171      PMCID: PMC8759308          DOI: 10.1164/rccm.202104-0847OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  28 in total

1.  The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.

Authors:  Robert Brownell; Teng Moua; Travis S Henry; Brett M Elicker; Darin White; Eric Vittinghoff; Kirk D Jones; Anatoly Urisman; Carlos Aravena; Kerri A Johannson; Jeffrey A Golden; Talmadge E King; Paul J Wolters; Harold R Collard; Brett Ley
Journal:  Thorax       Date:  2017-01-12       Impact factor: 9.139

2.  Comprehensive volumetric optical microscopy in vivo.

Authors:  Seok H Yun; Guillermo J Tearney; Benjamin J Vakoc; Milen Shishkov; Wang Y Oh; Adrien E Desjardins; Melissa J Suter; Raymond C Chan; John A Evans; Ik-Kyung Jang; Norman S Nishioka; Johannes F de Boer; Brett E Bouma
Journal:  Nat Med       Date:  2006-11-19       Impact factor: 53.440

3.  Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial.

Authors:  Ganesh Raghu; David Lynch; J David Godwin; Richard Webb; Thomas V Colby; Kevin O Leslie; Juergen Behr; Kevin K Brown; James J Egan; Kevin R Flaherty; Fernando J Martinez; Athol U Wells; Lixin Shao; Huafeng Zhou; Patricia S Pedersen; Rohit Sood; A Bruce Montgomery; Thomas G O'Riordan
Journal:  Lancet Respir Med       Date:  2014-02-18       Impact factor: 30.700

4.  Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function.

Authors:  Carlo Albera; Ulrich Costabel; Elizabeth A Fagan; Marilyn K Glassberg; Eduard Gorina; Lisa Lancaster; David J Lederer; Steven D Nathan; Dominique Spirig; Jeff J Swigris
Journal:  Eur Respir J       Date:  2016-07-28       Impact factor: 16.671

5.  Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS.

Authors:  Ulrich Costabel; Yoshikazu Inoue; Luca Richeldi; Harold R Collard; Inga Tschoepe; Susanne Stowasser; Arata Azuma
Journal:  Am J Respir Crit Care Med       Date:  2016-01-15       Impact factor: 21.405

Review 6.  Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.

Authors:  David A Lynch; Nicola Sverzellati; William D Travis; Kevin K Brown; Thomas V Colby; Jeffrey R Galvin; Jonathan G Goldin; David M Hansell; Yoshikazu Inoue; Takeshi Johkoh; Andrew G Nicholson; Shandra L Knight; Suhail Raoof; Luca Richeldi; Christopher J Ryerson; Jay H Ryu; Athol U Wells
Journal:  Lancet Respir Med       Date:  2017-11-15       Impact factor: 30.700

7.  Quantitative assessment of airway remodelling and response to allergen in asthma.

Authors:  David C Adams; Alyssa J Miller; Matthew B Applegate; Josalyn L Cho; Daniel L Hamilos; Alex Chee; Jasmin A Holz; Margit V Szabari; Lida P Hariri; R Scott Harris; Jason W Griffith; Andrew D Luster; Benjamin D Medoff; Melissa J Suter
Journal:  Respirology       Date:  2019-03-07       Impact factor: 6.424

8.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

9.  Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Authors:  Luca Richeldi; Roland M du Bois; Ganesh Raghu; Arata Azuma; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Kevin R Flaherty; David M Hansell; Yoshikazu Inoue; Dong Soon Kim; Martin Kolb; Andrew G Nicholson; Paul W Noble; Moisés Selman; Hiroyuki Taniguchi; Michèle Brun; Florence Le Maulf; Mannaïg Girard; Susanne Stowasser; Rozsa Schlenker-Herceg; Bernd Disse; Harold R Collard
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

10.  My approach to interstitial lung disease using clinical, radiological and histopathological patterns.

Authors:  K O Leslie
Journal:  J Clin Pathol       Date:  2009-05       Impact factor: 3.411

View more
  3 in total

1.  ERS International Congress 2021: highlights from the Clinical Techniques, Imaging and Endoscopy Assembly.

Authors:  Christina Bal; Casper Falster; Andre Carvalho; Nicole Hersch; Judith Brock; Christian B Laursen; Simon Walsh; Jouke Annema; Daniela Gompelmann
Journal:  ERJ Open Res       Date:  2022-05-23

Review 2.  Contemporary Concise Review 2021: Interstitial lung disease.

Authors:  Cormac McCarthy; Michael P Keane
Journal:  Respirology       Date:  2022-05-05       Impact factor: 6.175

3.  Endobronchial Optical Coherence Tomography for the Diagnosis of Fibrotic Interstitial Lung Disease: A Light at the End of the Tunnel?

Authors:  Daniel-Costin Marinescu; Christopher J Ryerson
Journal:  Am J Respir Crit Care Med       Date:  2021-11-15       Impact factor: 21.405

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.